Effect of Rifampicin Added to Antibiotics on Treatment Success in Cutibacterium Acnes Joint Prosthetic Infections

What this Trial Is About

Researchers are investigating the role of rifampicin in treating prosthetic joint infections caused by Cutibacterium acnes, which is involved in nearly 40% of shoulder prosthetic joint infections and is a leading cause of late-onset infections after hip and knee prosthesis. The study focuses on the challenges posed by biofilm-associated bacteria in these infections, which have slower growth and may be less responsive to antibiotics. Rifampicin is known for its activity against biofilm-related staphylococcal infections and is being evaluated for its effect on C. acnes infections. Participants receive either amoxicillin or moxifloxacin alone or combined with rifampicin for 12 weeks as antibiotic treatment during surgical revision of infected knee, hip, or shoulder prostheses. The study uses a randomized, parallel design comparing the antibiotic backbone alone versus the combination with rifampicin. Treatment choice between amoxicillin and moxifloxacin is at the investigators discretion. Rifampicin use is being assessed for its impact on treatment outcomes. Throughout the study, participants are monitored for treatment failure and adverse events related to rifampicin up to 24 months after completing antibiotics. The main outcome is the rate of infection management failure 24 months post-treatment. Researchers also track probable failures and failures at 12 months. Safety assessments focus on adverse events during rifampicin therapy. The total study duration includes treatment and long-term follow-up to evaluate both effectiveness and safety.

Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections